Prostate Cancer
Prostate Cancer arises from glandular cells of the prostate and spans a spectrum from localized disease to metastatic forms. Genomic changes can inform therapy selection.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Prostate Cancer in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| BRCA1 and BRCA2 |
|
Defined at the solid tumor level and applicable to Prostate Cancer and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Prostate Cancer. Select a therapy to view the specific approval and eligible tests.
BRCA1 and BRCA2 (alterations (including mutations))
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)